IL101858A0 - Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker - Google Patents

Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker

Info

Publication number
IL101858A0
IL101858A0 IL101858A IL10185892A IL101858A0 IL 101858 A0 IL101858 A0 IL 101858A0 IL 101858 A IL101858 A IL 101858A IL 10185892 A IL10185892 A IL 10185892A IL 101858 A0 IL101858 A0 IL 101858A0
Authority
IL
Israel
Prior art keywords
angiotensin
antagonist
combination
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL101858A
Other versions
IL101858A (en
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of IL101858A0 publication Critical patent/IL101858A0/en
Publication of IL101858A publication Critical patent/IL101858A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL10185892A 1991-05-15 1992-05-14 Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker IL101858A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15

Publications (2)

Publication Number Publication Date
IL101858A0 true IL101858A0 (en) 1992-12-30
IL101858A IL101858A (en) 1996-08-04

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10185892A IL101858A (en) 1991-05-15 1992-05-14 Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker

Country Status (11)

Country Link
EP (1) EP0584250A1 (en)
JP (1) JP2930252B2 (en)
AU (1) AU664375B2 (en)
CA (1) CA2103276A1 (en)
CZ (1) CZ281570B6 (en)
IE (1) IE921534A1 (en)
IL (1) IL101858A (en)
MX (1) MX9202243A (en)
NZ (1) NZ242724A (en)
WO (1) WO1992020342A1 (en)
ZA (1) ZA923557B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (en) 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
PT804229E (en) 1995-03-16 2003-06-30 Pfizer USE OF AMLODIPINE FROM ONE OF ITS SAFETY OR DEFELODIPINE IN COMBINATION WITH AN INHIBITOR OF ANGIOTENSIN CONVERSION (ACE) FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF NON-ISCHEMIC CONGESTIVE CARDIAC INSUFFICIENCY
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
ID27664A (en) 1998-07-10 2001-04-19 Novartis Ag ANTIHIPERSENSITIVE COMBINATION OF VALSARTAN AND CALCULATOR OF CALCIUM CHANNELS
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (en) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP3045174A1 (en) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (en) * 1986-11-20 1990-06-01 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
KR100222252B1 (en) * 1990-12-14 1999-10-01 스튜어트 알. 수터 Angiotensin ii receptor blocking compositions

Also Published As

Publication number Publication date
AU664375B2 (en) 1995-11-16
WO1992020342A1 (en) 1992-11-26
EP0584250A1 (en) 1994-03-02
IE921534A1 (en) 1992-11-18
EP0584250A4 (en) 1994-03-30
JP2930252B2 (en) 1999-08-03
AU2026992A (en) 1992-12-30
CA2103276A1 (en) 1992-11-16
NZ242724A (en) 1994-09-27
JPH06508128A (en) 1994-09-14
ZA923557B (en) 1993-11-15
CZ281570B6 (en) 1996-11-13
IL101858A (en) 1996-08-04
CZ235193A3 (en) 1994-03-16
MX9202243A (en) 1992-11-01

Similar Documents

Publication Publication Date Title
IL101858A0 (en) Pharmaceutical compositions containing a combination of an angiotensin-ii antagonist and a calcium channel blocker
NZ244766A (en) Bi-aromatic compounds and pharmaceutical compositions
IL111007A0 (en) Composition containing rapamycin for oral administration
CZ99396A3 (en) Macrolide compounds and pharmaceutical composition containing thereof
GB9213393D0 (en) Pharmaceutical composition
GB9210579D0 (en) Pharmaceutical composition
GB9210974D0 (en) Pharmaceutical composition
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
AP9701160A0 (en) Compounds and pharmaceutical compositions containing them
HUT74746A (en) Pharmaceutical compositions containing p antagonist
AP9200356A0 (en) Pharmaceutical composition
GB9108080D0 (en) Pharmaceutical composition
IL117075A0 (en) Compounds having growth hormone releasing properties pharmaceutical compositions containing them and their use
IL102372A0 (en) Pharmaceutical composition containing a non-n-methyl-d-aspartate antagonist
NZ243627A (en) 3-deoxy-mannosamine derivatives and pharmaceutical compositions thereof; intermediate precursors
IL117076A0 (en) Compounds having growth hormone releasing properties pharmaceutical compositions containing them and their use
GB2251617B (en) Pharmaceutical compositions containing substituted 3-hydroxypyridin-4-ones
IL102435A0 (en) Pharmaceutical composition
IL104417A0 (en) Substituted dihydroindene and-acenaphthene derivatives and pharmaceutical compositions containing them
IL90189A0 (en) Pharmaceutical compositions containing a benzazepine-type calcium channel blocker
HUP9903619A3 (en) Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
GB2252497B (en) Pharmaceutical composition
GB9111477D0 (en) Pharmaceutical composition
GB9108129D0 (en) Pharmaceutical composition
GB9116274D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees